Orbimed Advisors LLC Tricida, Inc. Transaction History

Orbimed Advisors LLC

4 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2021 Feb 14, 2022	BUY	$4.19 - $9.56 $2.79 Million - $6.37 Million	666,667 Added 6.93%	10,280,947 $98.3 Million
Q4 2019 Feb 14, 2020	SELL	$29.6 - $43.71 $44.4 Million - $65.6 Million	-1,500,000 Reduced 13.5%	9,614,280 $363 Million
Q2 2019 Aug 14, 2019	BUY	$31.16 - $39.46 $7.01 Million - $8.88 Million	225,000 Added 2.07%	11,114,280 $439 Million
Q2 2018 Aug 14, 2018	BUY	$26.0 - $29.9 $283 Million - $326 Million	10,889,280 New	10,889,280 $326 Million

30K

124K

46.5K

Ticker TCDA
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 55,668,900
Market Cap $557K
Description
Tricida, Inc. operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track. The company ...

Get notified when there are updates to the investment portfolio of Orbimed Advisors LLC, based on Form 13F filings with the SEC.

Stay updated on Orbimed Advisors LLC with notifications on news.